London, Feb 11, 2025 – Echopoint was honoured to welcome Dr. Tim van De Hoef, a renowned Interventional Cardiologist from the University Medical Center Utrecht, to its offices today. Dr. van De Hoef, a key opinion leader in coronary physiology, brought invaluable expertise to the meeting, which centered around the latest developments in cardiac care and medical technologies.

The day began with an insightful demonstration of the iKOr physiology system, a cutting-edge diagnostic to measure CFR and FFR. Dr. van De Hoef had the opportunity to provide real-time feedback on the system’s design, offering key perspectives from a clinical standpoint that will shape future iterations of the technology. One of the day’s highlights was the cardiac gating demonstration, where Dr. van De Hoef observed real-time data related to cardiac synchronization.

In the afternoon, the group shifted focus to more strategic discussions, particularly on the design of clinical trials and studies. The collaborative conversations are expected to influence the next phase of clinical research, with a strong emphasis on the integration of emerging technologies into real-world applications. These discussions are crucial as they guide the direction of upcoming trials, ensuring they meet the evolving needs of both patients and clinicians.

The day concluded with a clinical advisory group session, where experts from various sectors of the healthcare industry came together to provide strategic guidance on the future of cardiac research. The insights shared will be pivotal in shaping clinical practices and research efforts going forward, ensuring that new innovations are effectively translated into tangible benefits for patients.

This meeting underscores Echopoint’s continued commitment to revolutionizing cardiac care and medical technology. By fostering collaboration between leading experts, the company is staying at the forefront of innovation in diagnostics and treatment. With Dr. van De Hoef’s feedback and the combined expertise of the professionals involved, Echopoint is poised to make significant strides in improving outcomes for patients worldwide.